1. Home
  2. SUPN vs NATL Comparison

SUPN vs NATL Comparison

Compare SUPN & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • NATL
  • Stock Information
  • Founded
  • SUPN 2005
  • NATL 2023
  • Country
  • SUPN United States
  • NATL United States
  • Employees
  • SUPN N/A
  • NATL N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • NATL
  • Sector
  • SUPN Health Care
  • NATL
  • Exchange
  • SUPN Nasdaq
  • NATL Nasdaq
  • Market Cap
  • SUPN 1.9B
  • NATL 2.0B
  • IPO Year
  • SUPN 2012
  • NATL N/A
  • Fundamental
  • Price
  • SUPN $34.09
  • NATL $26.22
  • Analyst Decision
  • SUPN Hold
  • NATL Buy
  • Analyst Count
  • SUPN 1
  • NATL 4
  • Target Price
  • SUPN $36.00
  • NATL $34.50
  • AVG Volume (30 Days)
  • SUPN 294.0K
  • NATL 320.5K
  • Earning Date
  • SUPN 11-04-2024
  • NATL 11-12-2024
  • Dividend Yield
  • SUPN N/A
  • NATL N/A
  • EPS Growth
  • SUPN N/A
  • NATL N/A
  • EPS
  • SUPN 0.08
  • NATL N/A
  • Revenue
  • SUPN $630,163,000.00
  • NATL $4,296,000,000.00
  • Revenue This Year
  • SUPN $4.01
  • NATL $4.80
  • Revenue Next Year
  • SUPN $0.10
  • NATL $3.12
  • P/E Ratio
  • SUPN $357.31
  • NATL N/A
  • Revenue Growth
  • SUPN N/A
  • NATL 4.25
  • 52 Week Low
  • SUPN $23.05
  • NATL $18.42
  • 52 Week High
  • SUPN $35.56
  • NATL $35.29
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 59.46
  • NATL 38.58
  • Support Level
  • SUPN $33.73
  • NATL $26.47
  • Resistance Level
  • SUPN $35.56
  • NATL $27.69
  • Average True Range (ATR)
  • SUPN 0.79
  • NATL 0.74
  • MACD
  • SUPN 0.05
  • NATL -0.15
  • Stochastic Oscillator
  • SUPN 56.91
  • NATL 14.80

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About NATL NCR Atleos Corporation

NCR Atleos Corp is financial technology company providing self-directed banking solutions to a global customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. They manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications & Technology.

Share on Social Networks: